Brilinta™ (
ticagrelor) is a prescription medication approved to prevent harmful blood clots from forming in people who have been hospitalized with chest pain or have had a certain type of
heart attack. These conditions are often known as acute coronary syndrome (ACS).
Brilinta is also used in combination with aspirin to reduce the risk of future heart attacks,
strokes, or blood clots in a stent (a tube placed in an artery of the heart during an
angioplasty procedure).
Who Makes This Medication?
Brilinta is manufactured by AstraZeneca LP.
This medication is an antiplatelet drug. It helps to prevent blood platelets from sticking together (an important step in clot formation). Brilinta is similar to an older antiplatelet medication known as
Plavix® (
clopidogrel).
Brilinta is intended to be taken with aspirin, which works with Brilinta to prevent platelets from sticking together. This medication and aspirin are similar but work on different types of receptors on the platelets.
Clinical studies have shown Brilinta to be more effective than Plavix (clopidogrel) for preventing heart-related deaths, as well as heart attacks.
There was little or no difference between the two medications for preventing strokes.
HealthSavvy Sign In
|
